Drugs / Merimepodib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00088504 | Jul 2004 → Oct 2006 | chronic hepatitis C virus infection | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04410354 Comparator | Jun → Dec 2020 | COVID-19 | ViralClear Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Merimepodib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088504 ↗ |
| Known as | MMPD | “The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with...” NCT04410354 ↗1“Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC)” PMID 19852040 ↗ Dec 2009 |
| Known as | VI-21,497 | ChEMBL registry synonym — accepted as the source's own label CHEMBL304087 ↗ |
| Known as | VX-497 | ChEMBL registry synonym — accepted as the source's own label CHEMBL304087 ↗ |
| Action | Inhibit | “Inosine-5'-monophosphate dehydrogenase 1 inhibitor” CHEMBL304087 ↗1“inosine monophosphate dehydrogenase inhibitor” PMID 19852040 ↗ Dec 2009 |
| Modality | Small molecule | — CHEMBL304087 ↗ |
| Route | Oral | “orally administered” PMID 19852040 ↗ Dec 2009 |
| Target | IMPDH1 | “Inosine-5'-monophosphate dehydrogenase 1 inhibitor” CHEMBL304087 ↗ |